IVERIC bio, Inc. (NASDAQ: ISEE)
Some price data may be temporarily unavailable.
IVERIC bio, Inc. Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
IVERIC bio, Inc. Company Info
News & Analysis
Why Iveric Bio Stock Is Skyrocketing This Week
Investors are applauding the company's late-stage clinical results for its lead pipeline candidate.
Here's Why Iveric Bio Stock Is Rocketing Higher Today
Mixed results from Apellis Pharmaceuticals are good news for Iveric Bio's geographic atrophy program.
Why Iveric Bio Is Skyrocketing 24% Today
An upsized public offering has investors increasingly confident about its prospects.
These Were the 10 Best Stocks of 2019
Seven biotechs led the way.
INDUSTRY FOCUS // Healthcare // 12-14-2016 // Segment 1/2
Ophthotech's future is in jeopardy following a high-profile phase 3 failure.
Here's Why Ophthotech Corporation Is Being Obliterated Today
Shares collapse after the company reports disappointing results from two phase 3 clinical trials.
Cohen's Point72 Bets Big Ahead of Ophthotech Corp. Trial Results
Ahead of pivotal phase 3 study results for Fovista, hedge-fund icon Steven Cohen's Point72 has reported a 5% ownership stake in Ophthotech.
Here's Why Ophtotech Corporation Dropped 16.5% in September
Shares drop over new concerns regarding the company's lead compound.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.